<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01621009</url>
  </required_header>
  <id_info>
    <org_study_id>1998-369</org_study_id>
    <secondary_id>P50CA084724</secondary_id>
    <secondary_id>P50DA019706</secondary_id>
    <nct_id>NCT01621009</nct_id>
  </id_info>
  <brief_title>Bupropion SR Plus Counseling for Smoking Cessation</brief_title>
  <official_title>A Randomized Controlled Clinical Trial of Bupropion SR and Individual Smoking Cessation Counseling</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to determine if bupropion plus counseling was more effective
      than bupropion alone or counseling alone in helping smokers quit smoking.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2001</start_date>
  <completion_date type="Actual">October 2003</completion_date>
  <primary_completion_date type="Actual">October 2002</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>7-day Point Prevalence Abstinence From Smoking at 6 Months</measure>
    <time_frame>6 months</time_frame>
    <description>No smoking, not even a puff, during the 7 days prior to the 6 month follow-up. Biochemically confirmed.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">463</enrollment>
  <condition>Tobacco Dependence</condition>
  <condition>Smoking</condition>
  <arm_group>
    <arm_group_label>Active bupropion + counseling</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active bupropion SR plus eight 10-minute individual counseling sessions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active bupropion , No counseling</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active bupropion, No counseling, only medication checks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo medication + counseling</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo bupropion plus eight 10-minute individual counseling sessions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo medication, No counseling</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo bupropion, No counseling, just medication checks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active bupropion + counseling</intervention_name>
    <description>Medications-Pre-quit: 150 mg bupropion per day 7 days before quit attempt, then 150 mg twice daily for 4 days before quit attempt; then 150 mg bupropion twice daily for eight weeks.
Counseling-Pre-quit: two 10 minutes sessions before quit date; eight 10-minute sessions post quit date.</description>
    <arm_group_label>Active bupropion + counseling</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active bupropion, No counseling</intervention_name>
    <description>Medication - 150 mg bupropion per day starting week before quit day, then 150 mg twice daily 3 days before quit day, then 150 mg twice daily for eight weeks after quit day.
Counseling: No cessation counseling, only medication checks</description>
    <arm_group_label>Active bupropion , No counseling</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo medication + counseling</intervention_name>
    <description>Placebo bupropion once daily 7 days before quit day, then twice daily 4 days before quit attempt, then twice daily for 8 weeks after quit day.
Counseling: Two 10-minutes sessions before quit day, then eight 10-minutes sessions for eight weeks after quit day.</description>
    <arm_group_label>Placebo medication + counseling</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo medication, No counseling</intervention_name>
    <description>Pre-quit: Placebo medication once daily 7 days before quit day, then twice daily before quit day, then twice daily for 8 weeks after quit day.
Counseling: No counseling, just medication checks</description>
    <arm_group_label>Placebo medication, No counseling</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Smoke 10 or more cigarettes per day

          -  Expired carbon monoxide (CO) level greater than 9 parts per million (ppm)

          -  Motivated to quit smoking (score of 3 on 4-point self-report scale)

          -  Willing to fulfill study requirements

        Exclusion Criteria:

          -  Carbon monoxide breath test score below 9 ppm

          -  Serious psychopathology (bipolar disorder, psychosis)

          -  Center for Epidemiologic Studies Depression Scale CES-D)score over 16

          -  Contraindications for use of bupropion

          -  History of seizure disorder

          -  History of eating disorder

          -  Current heavy drinking

          -  Risk of pregnancy

          -  Current breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy B Baker, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Timothy B Baker, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UW Center for Tobacco Research and Intervention</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53711</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>McCarthy DE, Piasecki TM, Lawrence DL, Jorenby DE, Shiffman S, Fiore MC, Baker TB. A randomized controlled clinical trial of bupropion SR and individual smoking cessation counseling. Nicotine Tob Res. 2008 Apr;10(4):717-29. doi: 10.1080/14622200801968343.</citation>
    <PMID>18418793</PMID>
  </results_reference>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2012</study_first_submitted>
  <study_first_submitted_qc>June 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2012</study_first_posted>
  <results_first_submitted>May 27, 2015</results_first_submitted>
  <results_first_submitted_qc>December 16, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 27, 2016</results_first_posted>
  <last_update_submitted>December 16, 2015</last_update_submitted>
  <last_update_submitted_qc>December 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>smoking cessation medications</keyword>
  <keyword>smoking cessation counseling</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupropion</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants recruited from Madison, WI area through TV, radio, newspaper advertisements from January, 2001 to October 2002</recruitment_details>
      <pre_assignment_details>Participants were 1) phone screened, 2) invited to group orientation where signed consent was obtained, and 3) completed CO testing and office visit for physical exam. Participants were considered enrolled after passing all 3 steps and randomization occurred at enrollment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Active Bupropion + Counseling</title>
          <description>Active bupropion SR plus eight 10-minute individual counseling sessions.</description>
        </group>
        <group group_id="P2">
          <title>Active Bupropion , No Counseling</title>
          <description>Active bupropion, No counseling, only medication checks</description>
        </group>
        <group group_id="P3">
          <title>Placebo Medication + Counseling</title>
          <description>Placebo bupropion plus eight 10-minute individual counseling sessions</description>
        </group>
        <group group_id="P4">
          <title>Placebo Medication, No Counseling</title>
          <description>Placebo bupropion, No counseling, just medication checks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="113"/>
                <participants group_id="P2" count="116"/>
                <participants group_id="P3" count="121"/>
                <participants group_id="P4" count="113"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="65"/>
                <participants group_id="P3" count="58"/>
                <participants group_id="P4" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="51"/>
                <participants group_id="P3" count="63"/>
                <participants group_id="P4" count="53"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Active Bupropion + Counseling</title>
          <description>Active bupropion SR plus eight 10-minute individual counseling sessions.</description>
        </group>
        <group group_id="B2">
          <title>Active Bupropion , No Counseling</title>
          <description>Active bupropion, No counseling, only medication checks</description>
        </group>
        <group group_id="B3">
          <title>Placebo Medication + Counseling</title>
          <description>Placebo bupropion plus eight 10-minute individual counseling sessions</description>
        </group>
        <group group_id="B4">
          <title>Placebo Medication, No Counseling</title>
          <description>Placebo bupropion, No counseling, just medication checks</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="113"/>
            <count group_id="B2" value="116"/>
            <count group_id="B3" value="121"/>
            <count group_id="B4" value="113"/>
            <count group_id="B5" value="463"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                    <measurement group_id="B2" value="116"/>
                    <measurement group_id="B3" value="121"/>
                    <measurement group_id="B4" value="113"/>
                    <measurement group_id="B5" value="463"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.76" spread="11.39"/>
                    <measurement group_id="B2" value="41.03" spread="12.64"/>
                    <measurement group_id="B3" value="37.82" spread="12.82"/>
                    <measurement group_id="B4" value="39.42" spread="11.34"/>
                    <measurement group_id="B5" value="38.76" spread="12.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="63"/>
                    <measurement group_id="B4" value="61"/>
                    <measurement group_id="B5" value="233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="58"/>
                    <measurement group_id="B4" value="52"/>
                    <measurement group_id="B5" value="230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                    <measurement group_id="B2" value="116"/>
                    <measurement group_id="B3" value="121"/>
                    <measurement group_id="B4" value="113"/>
                    <measurement group_id="B5" value="463"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>7-day point prevalence abstinence</title>
          <description>Participants provided breath samples for carbon monoxide(CO)testing at all visits and provided a blood sample to assess cotinine (the first metabolite of nicotine)levels at baseline and again at end of treatment.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Abstinent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Abstinent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="106"/>
                    <measurement group_id="B4" value="99"/>
                    <measurement group_id="B5" value="397"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>7-day Point Prevalence Abstinence From Smoking at 6 Months</title>
        <description>No smoking, not even a puff, during the 7 days prior to the 6 month follow-up. Biochemically confirmed.</description>
        <time_frame>6 months</time_frame>
        <population>Full intent-to-treat sample</population>
        <group_list>
          <group group_id="O1">
            <title>Bupropion + Counseling</title>
            <description>Active bupropion + 8 weeks counseling: Medications: Pre-quit - 150mg bupropion SR per day 3 days before quit day, then 150mg twice a day 4 days before quit day; 150mg bupropion SR twice daily for 8 weeks after the quit date.
Counseling: Pre-quit - Two 10-minute sessions; Post-quit: Eight weekly 10-minute sessions</description>
          </group>
          <group group_id="O2">
            <title>Bupropion, No Counseling</title>
            <description>Active bupropion, No counseling: Medications: Medications: Pre-quit - 150mg bupropion SR per day 3 days before quit day, then 150mg twice a day 4 days before quit day; 150mg bupropion SR twice daily for 8 weeks after the quit date. No cessation counseling, medication management and assessment only.</description>
          </group>
          <group group_id="O3">
            <title>Placebo + Counseling</title>
            <description>: Medications: Pre-quit - Placebo bupropion one per day 3 days before quit day, then two per day 4 days before quit day; placebo bupropion twice daily for 8 weeks after the quit date.
Counseling: Pre-quit - Two 10-minute sessions; Post-quit: Eight weekly 10-minute sessions</description>
          </group>
          <group group_id="O4">
            <title>Placebo, No Counseling</title>
            <description>: Medications: Pre-quit - Placebo bupropion one per day 3 days before quit day, then two per day 4 days before quit day; placebo bupropion twice daily for 8 weeks after the quit date.
No cessation counseling, medication management and assessment only.</description>
          </group>
        </group_list>
        <measure>
          <title>7-day Point Prevalence Abstinence From Smoking at 6 Months</title>
          <description>No smoking, not even a puff, during the 7 days prior to the 6 month follow-up. Biochemically confirmed.</description>
          <population>Full intent-to-treat sample</population>
          <units>Number of abstinent participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="116"/>
                <count group_id="O3" value="121"/>
                <count group_id="O4" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.78</ci_lower_limit>
            <ci_upper_limit>3.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.52</ci_lower_limit>
            <ci_upper_limit>2.44</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo Medication</title>
          <description>Medications: Pre-quit – one placebo pill for 3 days before quit day, then one placebo pill twice a day 4 days before quit day for 8 weeks after the quit date.</description>
        </group>
        <group group_id="E2">
          <title>Active Medication</title>
          <description>Pre-quit – 150mg bupropion SR per day 3 days before quit day, then 150mg twice a day 4 days before quit day; 150mg bupropion SR twice daily for 8 weeks after the quit date.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="94" subjects_at_risk="229"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>depression</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="234"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="234"/>
                <counts group_id="E2" events="35" subjects_affected="35" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="234"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="229"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Feeling jittery</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="234"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="229"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>upper respiratory infection</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="234"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="229"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Lack of a no-treatment control condition; limited ability to generalize to broader population</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Timothy Baker, PhD, Director of Research</name_or_title>
      <organization>University of Wisconsin Center for Tobacco Research and Intervention</organization>
      <phone>(608) 262-7568</phone>
      <email>tbb@ctri.wisc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

